Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Use code: EVOLVE for 20% off Guaranteed Delivery Are you ready to EVOLVE
Expand Patient Access: Addressing affordability and improving healthcare access, particularly in emerging markets like India and China, will be key to market penetration
MEDI4166 was designed to combine the mechanisms of action of PCSK9 inhibitors and GLP-1 agonists/analogues, described above, to treat patients with type 2 diabetes who require additional control of blood glucose and LDL-cholesterol levels, with the goal of reducing overall cardiovascular risk
For maximum effectiveness, extend this to 2-3 hours post-administration before consuming significant calories
US$ 27.26
US$ 27.89
US$ 28.94
US$ 21.31
US$ 29.43
US$ 22.78
